Treatment of hyperfunctioning thyroid nodules by percutaneous ethanol injection by Larijani, Bagher et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Endocrine Disorders
Open Access BMC Endocrine Disorders  2002,  2 x Research article
Treatment of hyperfunctioning thyroid nodules by percutaneous 
ethanol injection
Bagher Larijani*1, Mohammad Pajouhi1, Hossein Ghanaati2, Mohammad-
Hassan Bastanhagh1, Fereshteh Abbasvandi1, Kazem Firooznia2, 
Mahmood Shirzad1, Mohammad-Reza Amini1, Maryam Sarai1, 
Nasreen Abbasvandi1 and Reza Baradar-Jalili1
Address: 1Endocrinology & Metabolism Research Centre, Tehran University of Medical Sciences, Tehran, Iran and 2Medical Imaging Centre, Imam 
Khomeini University Hospital, Tehran, Iran
E-mail: Bagher Larijani* - emrc@sina.tums.ac.ir; Mohammad Pajouhi - emrc@sina.tums.ac.ir; Hossein Ghanaati - emrc@sina.tums.ac.ir; 
Mohammad-Hassan Bastanhagh - emrc@sina.tums.ac.ir; Fereshteh Abbasvandi - emrc@sina.tums.ac.ir; 
Kazem Firooznia - emrc@sina.tums.ac.ir; Mahmood Shirzad - emrc@sina.tums.ac.ir; Mohammad-Reza Amini - emrc@sina.tums.ac.ir; 
Maryam Sarai - emrc@sina.tums.ac.ir; Nasreen Abbasvandi - emrc@sina.tums.ac.ir; Reza Baradar-Jalili - emrc@sina.tums.ac.ir
*Corresponding author
Keywords: Hot Thyroid Nodules, Treatment, Ethanol, Thyrotoxicosis, Ultrasonography
Abstract
Background: Autonomous thyroid nodules can be treated by a variety of methods. We assessed
the efficacy of percutaneous ethanol injection in treating autonomous thyroid nodules.
Methods: 35 patients diagnosed by technetium-99 scanning with hyperfunctioning nodules and
suppressed sensitive TSH (sTSH) were given sterile ethanol injections under ultrasound guidance.
29 patients had clinical and biochemical hyperthyroidism. The other 6 had sub-clinical
hyperthyroidism with suppressed sTSH levels (<0.24 µIU/ml) and normal thyroid hormone levels.
Ethanol injections were performed once every 1–4 weeks. Ethanol injections were stopped when
serum T3, T4 and sTSH levels had returned to normal, or else injections could no longer be
performed because significant side effects. Patients were followed up at 3, 6 and, in 15 patients, 24
months after the last injection.
Results: Average pre-treatment nodule volume [18.2 ± 12.7 ml] decreased to 5.7 ± 4.6 ml at 6
months follow-up [P < 0.001]. All patients had normal thyroid hormone levels at 3 and 6 months
follow-up [P < 0.001 relative to baseline]. sTSH levels increased from 0.09 ± 0.02 µIU/ml to 0.65 ±
0.8 µIU/ml at the end of therapy [P < 0.05]. Only 3 patients had persistent sTSH suppression at 6
months post-therapy. T4 and sTSH did not change significantly between 6 months and 2 years [P >
0.05]. Ethanol injections were well tolerated by the patients, with only 2 cases of transient
dysphonia.
Conclusion: Our findings indicate that ethanol injection is an alternative to surgery or radioactive
iodine in the treatment of autonomous thyroid nodules.
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Background
Conventional therapy for hyperfunctioning thyroid nod-
ules includes radioactive iodine, surgery, and long-term
pharmacotherapy [1,2]. Radioactive iodine therapy is ac-
companied by a 10–40% risk of hypothyroidism [1–3]. A
third option, introduced over the past twelve years, has
been percutaneous ethanol injection (PEI) [4–19]. This
method was first used in the treatment of hepatic adeno-
mas and, subsequently, thyroid nodules [4,5,8]. It is par-
ticularly suitable for patients who are not candidates for
surgery or radioiodine therapy. The tissues inside the nod-
ule undergo fibrosis following ethanol injection [6]. The
present study aims to evaluate the outcome and complica-
tions of PEI therapy for hyperfunctioning nodules. No
study of this type and size has so far been carried out in
Iran, a country with a significant prevalence of thyroid dis-
orders and, until recently, an endemic goitre region.
Methods
Patients
This is a prospective study of the efficacy of percutaneous
ethanol injection in a consecutive series of patients with a
hyperfunctioning thyroid nodule. Patients meeting entry
criteria were enrolled in the study and then followed up at
specific times following completion of therapy. Entry cri-
teria were a dominant hyperfunctioning thyroid nodule,
as determined by technetium-99 scanning, a suppressed
sensitive TSH (sTSH), and negative thyroid aspiration cy-
tology. Patients on methimazole had their medication
gradually tapered during the second and third PEI ses-
sions, and discontinued before completion of therapy.
Complete response was defined as normalisation of thy-
roid function tests and absence of clinical symptoms.
Written informed consent was obtained from every pa-
tient. The study was approved by the relevant institutional
review committee.
Thyroid Function Tests
Thyroid function tests were measured by second-genera-
tion radioimmunoassay (Kavoshyar, Tehran, Iran), and
sTSH by immunoradiometric assay (same manufacturer),
with intra- and inter-assay coefficients of variation for T3
of 3.3% and 7.5%, for T4 of 6.8% and 8.0%, and for TSH
of 5.8 and 4.9 percent. The normal ranges were T3 = 80–
230 ng/dl, T4 = 4.5–12.8 µg/ml, and TSH = 0.2–5 µIU/ml.
Imaging
Nodule volume was calculated automatically by the ultra-
sound machine, using the formula: length × width × thick-
ness  ×  π/6, which provides an approximation to the
volume of a spheroid, and is reported to be 80–85% accu-
rate [7].
Nodule Cytology
Every patient underwent a fine needle aspiration biopsy to
rule out malignancy. In patients with multinodular goitre,
the dominant nodule, as reported by 99Tm scanning, was
aspirated. In the single patient with two co-dominant
nodules, both nodules were aspirated. The cytology report
for every specimen was cystic colloid goitre, consisting of
abundant colloidal material, with many haemosiderin-
laden macrophages and scanty follicular cells, dispersed
throughout the specimen or else forming a loose honey-
comb monolayer of cells. The distinction between the lat-
ter entity and follicular neoplasia, a source of diagnostic
confusion when FNA is performed in patients with a hot
nodule, where the aspirate is commonly highly cellular,
was, in our samples, quite clear.
Ethanol Injection
The dimensions and volume of the nodules were meas-
ured by linear real-time ultrasonography, using a General
Electric Sonochrome machine, with an 8 MHz probe. Un-
der direct ultrasound guidance, 0.5–10 ml of sterile 95%
ethanol (Pasteur Institute Production Centre – Tehran,
Iran) was injected inside each nodule (0.1 ml per ml nod-
ule volume, using a disposable plastic syringe and 22-
gauge needle). Two patients had cystic nodules, which
were drained completely before administration of PEI.
The injection needle was kept in place for 1–2 minutes in
order to avoid any ethanol leakage, and patients were ad-
vised to take oral analgesia before injection. Injections
were performed once every 1–2 weeks. Patients were as-
sessed at the end of the treatment cycle and at 3 and 6
months afterwards. Thyroid function tests were per-
formed on 15 patients at the end of 2 years. Thyroid func-
tion tests were performed after 3–4 rounds of injection.
When hormone levels were found to be within the normal
range, PEI therapy was deemed successful and the injec-
tions, discontinued.
Statistical Analysis
The repeated measures and paired-t tests were used to
compare baseline and follow-up values, and Pearson's
correlation test to measure the strength of the linear rela-
tionship between initial nodule size and reduction in
nodule volume. Complete response was defined as a re-
duction in both nodule size and thyroid hormone levels,
and normalization of sTSH levels.
Results
Demographics
35 patients (30 women, 5 men) aged 16–70 years (mean
age ± SD: 38.6 ± 12.4) received PEI therapy. 18 patients
(54%) had solitary hyperfunctioning nodules on 99Tc
scanning, with complete suppression of the remaining
thyroid tissue. 16 patients (46%) had multinodular goitre
with a dominant hyperfunctioning nodule. 1 patient hadBMC Endocrine Disorders 2002, 2 http://www.biomedcentral.com/1472-6823/2/3
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two hot nodules. 29 patients (82.9%) were hyperthyroid
(suppressed sTSH and elevated T3 and T4 levels), and 6 pa-
tients (17.1 %) had sub-clinical hyperthyroidism with
sTSH suppression and normal levels of thyroid hormones.
Nodule Size
Mean pre-treatment volume in the 36 nodules was 18.2 ±
12.7 ml (range = 4–44 ml). Mean post-PEI nodule volume
decreased to 7.5 ± 5.3 ml (range = 1–21 ml), reaching 5.7
± 4.6 ml (range 0.5–20 ml) at 6 months follow-up [P <
0.001]. Average volume reduction was 12.48 ± 10.6 ml,
with a linear correlation between initial nodule volume
and the magnitude of volume reduction: the greater the
initial nodule volume, the greater the reduction in nodule
volume [r = 0.94, P = 0.007].
Thyroid Function Tests
Sensitive TSH levels were suppressed in every patient be-
fore start of therapy, with a mean level of 0.09 ± 0.02 µIU/
ml. In the sub-clinical hyperthyroid group, sTSH had risen
to a mean of 0.42 ± 0.47 µIU/ml by the end of treatment,
with 3 out of 6 patients still having sTSH levels below the
normal range. At 3 months, the mean sTSH level in this
group increased to 1.18 ± 1.3 µIU/ml, with only 1 patient
showing persistent TSH suppression. At 6-months follow
up, sTSH levels had normalised in all 6 patients, with a
mean sTSH level of 1.15 ± 0.97 µIU/ml [P = 0.04].
In the hyperthyroid group, mean sTSH concentration at
the end of therapy had risen to 0.69 ± 0.9 µIU/ml [P =
0.02]. Of the 9 hyperthyroid patients (31.0% of the hyper-
thyroid group) whose sTSH levels had not shown a satis-
factory response to PEI therapy, only 3 patients (10.3%)
had suppressed TSH at 6 months follow-up. By the end of
therapy, all patients were clinically asymptomatic, with
normal levels of T3 and T4 [P < 0.001]. The success rate for
PEI was 91.4%, with only 3 patients (8.6%) exhibiting
persistent sTSH suppression with normal peripheral thy-
roid hormone levels. These three patients all had solitary
hot nodules. Two were women, aged 37 and 25, and the
third was a 44 year-old man.
Complications
No lasting or serious complication was observed with PEI
therapy. 2 cases of transient dysphonia were reported.
Both patients recovered completely. Examination by an
ENT specialist showed transient vocal cord paralysis and
subsequent full recovery. Table 2 shows the number of pa-
tients experiencing complications during treatment. All
complications improved within minutes, except for 2 ep-
isodes of fever, which persisted for 24–48 hours, and 2
cases of transient dysphonia, which resolved fully after 1
week and 6 months.
Discussion
Hyperfunctioning thyroid nodules are common, yet there
is controversy about their management [1,2,21]. The dif-
ferent modalities used include surgery, radioiodine, and
Table 1: Pre- and post-pei thyroid function in 35 patients with hot nodules
Initial Assessment and Follow-up
Before PEI (n = 35) After PEI (n = 35) 3 months (n = 35) 6 months (n = 35) 2 years (n = 15)
T3 270.6 ± 99.6 169.05 ± 58.3* 164.5 ± 52.5* 157.6 ± 46.7* 189.2 ± 61.7‡
T4 14.9 ± 4.6 9.6 ± 3.04* 9.9+2.8* 9.4+2.4* 10.2 ± 2.46‡
TSH 0.09 ± 0.02 0.65 ± 0.8† 0.62 ± 0.8† 0.71 ± 0.8† 0.86 ± 1.5†
NV (ml) 18.2 ± 12.7 7.5 ± 5.3 - 5.7 ± 4.6 -
TTV (ml) - - - - -
Normal Ranges: T3 = 80–230 ng/dl T4 = 4.5–12.8 µg/ml TSH = 0.2–5 µIU/ml Legend: * Significant change [P < 0.001] compared to pre-treatment 
†Significant change [P < 0.05] compared to pre-treatment ‡ No significant change [P > 0.05] compared to follow-up at 6 months Abbreviations: NV: 
nodule volume TTV: total thyroid volume PEI: percutaneous ethanol injection
Table 2: Complications of Therapy in 35 Patients with Hot Nod-
ules Treated by Percutaneous Ethanol Injection
Complication Number of patients






Bruising at site of injection 2
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percutaneous ethanol injection [1,22]. The studies carried
out over the past decade on the efficacy of PEI in the treat-
ment of autonomous thyroid nodules indicate that it is ef-
fective, requires no anaesthesia, and carries minimal risk
[19,23]. In our study, PEI also proved to be an effective
treatment for patients with hyperfunctioning thyroid nod-
ules and either clinical or sub-clinical hyperthyroidism.
None of our patients reported symptoms of hyperthy-
roidism after PEI and all of them achieved normal periph-
eral thyroid hormone levels. At 3 months follow-up, only
3 patients showed persistent sTSH suppression in spite of
normal thyroid hormone levels. Reduction in the volume
of nodules was significant at 3 months [P < 0.001], with
an average value of l2.48 ± 10.6 ml per nodule. The suc-
cess rate for this study (91.3%) is consistent with that re-
ported elsewhere (54–100%) [18,19,23,25]. Two large
studies from Italy, one on 132 patients followed up over
8.5 years [23] and the other on 117 patients followed up
over 5 years [24], suggest that PEI be recommended as
treatment for hyperfunctioning thyroid adenoma with
sub-clinical hyperthyroidism. The success rate in our pa-
tients is higher, however, than that reported in a number
of larger series, notably that reported by Lippi et al [24], in
which the overall success rate was 45.9% at 3 months, in-
creasing to 73.9% at one year. 99 Tm scans were only per-
formed before treatment in our patients; follow-up
scanning may well have reduced our success rate too.
PEI can also be recommended as alternative therapy in pa-
tients at high-risk for surgery (even when the nodules are
large) or for patients in whom radioactive iodine may
have relative contraindication(s) [2,18,25,27]. Many au-
thors further stress that PEI should only be carried out in
centres thoroughly familiar with the technique required
[28–31]. Transient dysphonia (spontaneous recovery over
a period of weeks or months) has been reported in 2–5%
of cases [20,30,32]. The pathology in every case has been
either direct chemical injury to the recurrent laryngeal
nerves, secondary to alcohol leakage outside the nodule,
or nerve injury due to a sudden elevation in pressure in-
side the nodule. Two cases of transient vocal cord paraly-
sis were seen in our patients; one recovered fully after 1
week, the other fully after 6 months. Real-time ultrasound
used to monitor the PEI procedure can identify ethanol
leakage, which shows up as a hyperechogenic area, as it is
happening. One group has suggested that, in order to
minimise the risk involved, a bolus of 2% Xylocaine (0.2–
0.5 ml) should be injected first in order to mark the injec-
tion path before PEI itself is begun [9]. We omitted this
approach because the nodules were all clearly identifiable
by ultrasound and there was little risk of leakage. Studies
have shown that ethanol produces coagulative necrosis of
nodular tissue through hemorrhagic infarction and vascu-
lar thrombosis [33,34]. Furthermore, in the area of viable
tissue surrounding the zone of biochemical ablation, en-
zyme activity is reduced. The areas of necrotic thyroid pa-
renchyma are clearly distinguishable from the seemingly
normal thyroid tissue surrounding them, which is free of
any evidence of inflammation [33,34]. The probability of
recurrence is virtually eliminated once granulation scar
tissue replaces the nodule. Hypothyroidism is not ob-
served even after prolonged follow-up [26,35]. Recurrence
of hyperthyroidism has not been reported in patients who
have had a complete response to PEI [26,35]. Our study
confirms this. It should be noted that a number of our pa-
tients had multinodular goitre, with more than one hot
nodule being detected on radioisotope scanning. In expe-
rienced hands, major complications of PEI, such as fibro-
sis of adjacent tissues or thrombogenesis within the large
vessels of the neck, are unlikely [33]. T3 and T4 levels in
both pre-toxic and toxic patients decreased significantly [P
< 0.001], and sTSH levels increased significantly, in re-
sponse to PEI [P < 0.01]. The most important factors in
predicting response to PEI are initial nodule volume and
the level of skill possessed by the physician performing
the procedure. Significant nodule shrinkage following PEI
has already been reported in the literature [36]. Our find-
ings confirm this. There exists a direct linear relationship
between reduction in nodule volume and initial nodule
volume (r = 0.94, p = 0.007), that is to say the greater the
initial size of the nodule, the larger the reduction in size.
PEI is also effective in non-toxic thyroid nodules in young
patients [6,36]. However, since the conversion rate for
non-toxic nodules (to toxic nodules) is 1.2–5.7 percent/
year depending on the follow-up series [37,38], many au-
thors recommend conservative therapy for patients with
non-toxic hot nodules. Furthermore, given that long-term
sub-clinical hyperthyroidism is associated with increased
bone turnover and accelerated bone demineralisation,
and that in patients with concomitant heart disease, the
increased quantity of hormone secreted by an autono-
mous nodule may produce arrhythmias or lead to cardiac
failure, treatment of hyperfunctioning nodules with sup-
pressed sTSH becomes necessary and PEI may be a reason-
able alternative in some cases [1,2,14,36,39].
Conclusions
We conclude that PEI is a method that is relatively inex-
pensive and does not require bed rest or hospitalisation.
It combines convenience with avoidance of surgical risks
and hypothyroidism associated with radioiodine therapy.
PEI is a more practical option in younger patients because
it leaves no residual surgical scar, involves no exposure to
radiation, is not associated with a long-term risk of hy-
pothyroidism, and leads to a reduction in nodule volume
without recourse to surgery.
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